CHAMPION-AF: Interpreting outcomes, net clinical benefit and clinically relevant bleeding

 

 

Overview:

Study investigators discuss late-breaking results, net clinical benefit and real-world clinical implications from the CHAMPION-AF clinical trial that compared the WATCHMAN FLX LAAC device head-to-head with NOACs as a first-line option for patients with nonvalvular atrial fibrillation.

This discussion covers three themes:

  1. About the CHAMPION-AF clinical trial and key results
  2. Clinical implications
  3. Future of LAAC devices and interventional cardiology for patients with nonvalvular atrial fibrillation

MODERATOR

Ken Stein, MD  

Ken Stein, MD
senior vice president and global chief medical officer
Boston Scientific

    

 
 
 
 

PANELISTS

Martin Leon, MD  

Martin Leon, MD
CHAMPION-AF study co-chair and Mallah Family professor of cardiology, chief innovation officer and director
Cardiovascular Data Science Center, Columbia University Medical Center

 Saibal Kar, MD  

Saibal Kar, MD
CHAMPION-AF study co-principal investigator and interventional cardiologist
Los Robles Regional Medical Center

 

This program was supported by:

 

 

Boston Scientific